甲氨蝶呤在巨细胞动脉炎治疗中的应用
Methotrexate treatment in the management of giant cell arteritis.
作者信息
Hernández-García C, Soriano C, Morado C, Ramos P, Fernández-Gutiérrez B, Herrero M, Bañares A, Jover J A
机构信息
Service of Rheumatology, Hospital Universitario San Carlos, Madrid, Spain.
出版信息
Scand J Rheumatol. 1994;23(6):295-8. doi: 10.3109/03009749409099276.
Eleven newly-diagnosed GCA patients were included in a prospective open study and treated with high initial prednisone doses, a quick-tapering CS schedule and weekly oral MTX for two years. It took a mean of 14 weeks to reach a 10 mg/day dose of prednisone and 29.8 weeks until steroid withdrawal. The mean cumulative dose of prednisone was 3.4 g. Two patients relapsed and five developed CS side effects. No serious MTX side effects were observed. Our results suggest that MTX is safe and could be useful in the therapy of GCA.
11例新诊断的巨细胞动脉炎患者被纳入一项前瞻性开放性研究，接受高初始剂量泼尼松、快速减量的糖皮质激素方案以及每周口服甲氨蝶呤治疗两年。平均14周达到泼尼松10mg/天的剂量，29.8周后停用类固醇。泼尼松的平均累积剂量为3.4g。2例患者复发，5例出现糖皮质激素副作用。未观察到严重的甲氨蝶呤副作用。我们的结果表明，甲氨蝶呤是安全的，可能对巨细胞动脉炎的治疗有用。
Zotero 插件